Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified Actos bladder cancer cases. Here at Leading Justice, we can customize your firm’s Actos advertising needs and help you sign up cases via internal cash buys. Our clients only pay an agency fee to cover the cost of Actos advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We cross-qualify all of our contacts as well, which means any data we generate that isn’t eligible for the target campaign is reviewed to determine whether it qualifies for another type of claim. By using advanced approaches to target contacts specifically associated with Actos and complications like bladder cancer, Leading Justice will increase your firm’s Actos case load. If you are interested in helping victims of alleged Actos side effects, our vast consumer reach and direct advertising strategies give you the competitive edge and confidence to allocate your full budget and rest easy knowing your money is being spent in the best way possible.
Each law firm we work with at Leading Justice plays a critical role in how we classify claims as qualified or not. While our extensive experience working with plaintiff law firms helps us recognize a great case when we see one, we will customize our Actos case intake specifications to the exact criteria you are seeking. If your firm has certain Actos qualifying case criteria you would like us to use, we can train our intake specialists to apply that specific criteria to each email and phone call they receive. By eliminating the middle man, Leading Justice offers clients an opportunity for internal cash buys of Actos data with no chance of fraud.
Actos and Bladder Cancer Litigation
When the diabetes drug Actos first garnered FDA approval in 1999, the medication was designed by Takeda Pharmaceuticals to be used in combination with diet and exercise to manage Type 2 diabetes in adults. Today, millions of Americans take anti-diabetes drugs like Actos (pioglitazone) in an effort to control blood sugar levels, despite increasing concerns about the potential risk of bladder cancer and other side effects associated with the medication. According to a drug safety communication issued by the FDA in 2011, for example, individuals with Type 2 diabetes who take Actos for more than a year may have an increased risk of suffering from bladder cancer side effects.
As new information comes to light about the alleged risk of bladder cancer among Actos users, patients throughout the country who believe they have been adversely affected by the diabetes drug are pursuing product liability claims against Takeda Pharmaceuticals. In fact, in April 2014, Takeda and its partner company Eli Lilly & Co. were ordered to pay a combined $9 billion in punitive damages after a Louisiana jury found that the companies’ diabetes drug caused a former Actos user to develop bladder cancer. The $9 billion verdict came in the first federal bellwether case to be tried over Actos side effects, and thousands more Actos cases are pending in state and federal courts throughout the country.